Related Experiment Video
Updated: Jul 9, 2026
09:03
Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
Published on: June 30, 2023
Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction
Donghua Xie1, Brian H Annex, Craig F Donatucci
1Duke University Medical Center Dur-ham, NC 27710, USA.
Asian Journal of Andrology
|December 19, 2007
Summary
Therapeutic angiogenesis shows promise for treating erectile dysfunction (ED) caused by hypercholesterolemia. Research focuses on growth factors and delivery methods to promote new blood vessel growth in penile tissues.
Area of Science:
- Vascular Biology
- Regenerative Medicine
- Urology
Background:
- Erectile dysfunction (ED) is often linked to vascular damage from conditions like hypercholesterolemia.
- Therapeutic angiogenesis aims to treat insufficient blood flow by stimulating new blood vessel formation.
- Recent advancements have deepened the understanding of angiogenesis mechanisms.
Purpose of the Study:
- To review the development of growth factors for hypercholesterolemia-induced ED.
- To examine various growth factors, delivery routes, and outcomes in animal models for ED therapy.
Main Methods:
- Focus on preclinical studies and animal models.
- Review of growth factor development and delivery strategies.
- Analysis of therapeutic angiogenesis for ED.
Main Results:
- Preclinical studies with growth factors showed initial promise for vascular diseases, including ED.
- Clinical translation of early approaches faced challenges.
- Novel therapies targeting multiple angiogenic pathways are under investigation.
Conclusions:
- Therapeutic angiogenesis holds significant potential for treating ED.
- The penis is a suitable target for gene therapy due to its accessibility and vascular characteristics.
- Continued research into novel angiogenic pathways and delivery methods is crucial for future treatments.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...